transforming growth factorbeta1 tgfbeta1 widelyexpressed cytokine major effects cell types tgfbeta1 anti inflammatory profibrotic casually linked fibrotic diseases eg pulmonary fibrosis tgfbeta1 secreted inactive complex ftgfbeta1 propeptide dimer called latency associated lap activation ltgfbeta1 key control point tgfbeta1 biology poorly understood thrombospondin1 tsp1 shown previously active ptgfbeta1 normal animals found lap ligand epitheliumspecific integrin alphavbeta6 cells expressing alphavbeta6 bind activate latent tgfbeta1 mechanism explain heretofore puzzling phenotype beta6 integrin knockout mice inflammation lung skin protection bleomycininduced pulmonary fibrosis results provide first evidence dysregulated tgfbeta1 activation causes fibrosis goals understand quantitatively interactions ltgfbeta alphavbeta6 lead activation develop animal model animal model knowledge explore fully biological role avbeta6mediated ltgfbeta1 activation aim 1 analyze activation mechanism focusing alphavbeta6 ltgfbeta1 interactions make tgfbeta1mull alphavbeta6 expressing cells specifically engineered forms ltgfbeta1 added either transfection recombinant protein system determine relative activatability two major forms ltgfbeta1 socalled small large latent complexes relative effects ltgfbeta1 concentration alphavbeta6 expression levels activation activatability soluble matrixbound latent tgfbeta1 integrin ltgfbeta1 stoichiometry required activation also assess influence integrinltgfbeta1 binding affinity activation results incorporated activation model related activation vivo aim 2 create mouse expressing mutant form ltgfbeta1 activated integrins rgd integrin binding sites lap mutated rge phenotypes mice beta6 integrin null mice compared confirm beta6 null phenotype due specifically loss tgfbeta1 activation interpret phenotype test ability rgdbinding integrins activate ltgfbeta1 finally cross rgetgfbeta1 mice tsp1 null mice assess summed effects two currently known tgfbeta1 activation mechanisms namely alphavbeta6 tsp1 results aims lead better understanding alphavbeta6mediated tgfbeta1 activation disease